Advertisement

Topics

Update: Novartis Takes on Blood Cancer with new Biosimilar Approval

04:50 EDT 19 Jun 2017 | Labiotech.eu

Update (19/06/2017): The EMA has cleared Sandoz’ Rixathon, a biosimilar to rituximab, making it the second oncology biosimilar in the EU. Novartis’ fourth EMA-approved biosimilar is set to unlock the billion-euro blood cancer and rheumatoid arthritis markets. Originally published on 24/04/2017 ...

This awesome article Update: Novartis Takes on Blood Cancer with new Biosimilar Approval appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Update: Novartis Takes on Blood Cancer with new Biosimilar Approval

NEXT ARTICLE

More From BioPortfolio on "Update: Novartis Takes on Blood Cancer with new Biosimilar Approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...